1. Home
  2. RNTX vs MLGO Comparison

RNTX vs MLGO Comparison

Compare RNTX & MLGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.70

Market Cap

42.9M

Sector

Health Care

ML Signal

HOLD

Logo MicroAlgo Inc.

MLGO

MicroAlgo Inc.

HOLD

Current Price

$4.06

Market Cap

38.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
MLGO
Founded
2001
2018
Country
United States
China
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
42.9M
38.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RNTX
MLGO
Price
$1.70
$4.06
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
118.7K
180.4K
Earning Date
05-14-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$87,132,230.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.91
Revenue Growth
N/A
6.21
52 Week Low
$1.02
$0.50
52 Week High
$2.22
$21.18

Technical Indicators

Market Signals
Indicator
RNTX
MLGO
Relative Strength Index (RSI) 69.15 57.67
Support Level $1.08 $3.70
Resistance Level $2.18 $4.73
Average True Range (ATR) 0.19 0.39
MACD 0.04 0.06
Stochastic Oscillator 83.78 55.84

Price Performance

Historical Comparison
RNTX
MLGO

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About MLGO MicroAlgo Inc.

MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.

Share on Social Networks: